Literature DB >> 10070865

Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas.

D Freihoff1, A Kempe, B Beste, B Wappenschmidt, E Kreyer, Y Hayashi, A Meindl, D Krebs, O D Wiestler, A von Deimling, R K Schmutzler.   

Abstract

PTEN is a novel tumour-suppressor gene located on chromosomal band 10q23.3. This region displays frequent loss of heterozygosity (LOH) in a variety of human neoplasms including breast carcinomas. The detection of PTEN mutations in Cowden disease and in breast carcinoma cell lines suggests that PTEN may be involved in mammary carcinogenesis. We here report a mutational analysis of tumour specimens from 103 primary breast carcinomas and constitutive DNA from 25 breast cancer families. The entire coding region of PTEN was screened by single-strand conformation polymorphism (SSCP) analysis and direct sequencing using intron-based primers. No germline mutations could be identified in the breast cancer families and only one sporadic carcinoma carried a PTEN mutation at one allele. In addition, all sporadic tumours were analysed for homozygous deletions by differential polymerase chain reaction (PCR) and for allelic loss using the microsatellite markers D10S215, D10S564 and D10S573. No homozygous deletions were detected and only 10 out of 94 informative tumours showed allelic loss in the PTEN region. These results suggest that PTEN does not play a major role in breast cancer formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070865      PMCID: PMC2362671          DOI: 10.1038/sj.bjc.6690121

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

1.  The role of MMAC1 mutations in early-onset breast cancer: causative in association with Cowden syndrome and excluded in BRCA1-negative cases.

Authors:  H C Tsou; D H Teng; X L Ping; V Brancolini; T Davis; R Hu; X X Xie; A C Gruener; C A Schrager; A M Christiano; C Eng; P Steck; J Ott; S V Tavtigian; M Peacocke
Journal:  Am J Hum Genet       Date:  1997-11       Impact factor: 11.025

2.  Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

Authors:  H Tashiro; M S Blazes; R Wu; K R Cho; S Bose; S I Wang; J Li; R Parsons; L H Ellenson
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus.

Authors:  B Singh; M M Ittmann; J J Krolewski
Journal:  Genes Chromosomes Cancer       Date:  1998-02       Impact factor: 5.006

4.  A study of the PTEN/MMAC1 gene in 136 breast cancer families.

Authors:  J Chen; P Lindblom; A Lindblom
Journal:  Hum Genet       Date:  1998-01       Impact factor: 4.132

Review 5.  Human cancer syndromes: clues to the origin and nature of cancer.

Authors:  E R Fearon
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

6.  Microsatellite instability analysis: a multicenter study for reliability and quality control.

Authors:  T Bocker; J Diermann; W Friedl; J Gebert; E Holinski-Feder; J Karner-Hanusch; M von Knebel-Doeberitz; K Koelble; G Moeslein; H K Schackert; H C Wirtz; R Fishel; J Rüschoff
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

7.  Somatic mutations of PTEN in glioblastoma multiforme.

Authors:  S I Wang; J Puc; J Li; J N Bruce; P Cairns; D Sidransky; R Parsons
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

8.  Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.

Authors:  J Boström; J M Cobbers; M Wolter; G Tabatabai; R G Weber; P Lichter; V P Collins; G Reifenberger
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

9.  PTEN gene mutations are seen in high-grade but not in low-grade gliomas.

Authors:  B K Rasheed; T T Stenzel; R E McLendon; R Parsons; A H Friedman; H S Friedman; D D Bigner; S H Bigner
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  16 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

Review 2.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

3.  The gene for human TATA-binding-protein-associated factor (TAFII) 170: structure, promoter and chromosomal localization.

Authors:  J A Van Der Knaap; V Van Den Boom; J Kuipers; M J Van Eijk; P C Van Der Vliet; H T Timmers
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

4.  Regulation of Signal Transduction by DJ-1.

Authors:  Stephanie E Oh; M Maral Mouradian
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

Review 5.  The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.

Authors:  W D Foulkes; J Rosenblatt; P O Chappuis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

6.  Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications.

Authors:  T Pal; N Hamel; D Vesprini; K Sanders; M Mitchell; N Quercia; N Ng Cheong; A Murray; W Foulkes; S A Narod
Journal:  Fam Cancer       Date:  2001       Impact factor: 2.375

Review 7.  Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment.

Authors:  Irene Brana; Lillian L Siu
Journal:  BMC Med       Date:  2012-12-11       Impact factor: 8.775

8.  PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling.

Authors:  Y Shrestha; E J Schafer; J S Boehm; S R Thomas; F He; J Du; S Wang; J Barretina; B A Weir; J J Zhao; K Polyak; T R Golub; R Beroukhim; W C Hahn
Journal:  Oncogene       Date:  2011-11-21       Impact factor: 9.867

9.  Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line.

Authors:  Gobind Singh; Leticia Odriozola; Hong Guan; Colin R Kennedy; Andrew M Chan
Journal:  BMC Cancer       Date:  2011-11-21       Impact factor: 4.430

Review 10.  PTEN deficiency: a role in mammary carcinogenesis.

Authors:  T Petrocelli; J M Slingerland
Journal:  Breast Cancer Res       Date:  2001-10-01       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.